NDA 022172 · Cheplapharm Arzneimittel Gmbh
Seroquel Xr
Quetiapine Fumarate · Oral
Last checked: Nov 20, 2026Latest source record: Nov 15, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Nov 15, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
398
129 Phase 3, 13 recruiting
FAERS reports
166,283
129,383 serious, 22,401 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 15, 2007 Original approval · Type 6 - New Indication (no longer used) ReviewSummary ReviewLetter
4 products under this application
- SEROQUEL XR · QUETIAPINE FUMARATE 400MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- SEROQUEL XR · QUETIAPINE FUMARATE 200MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- SEROQUEL XR · QUETIAPINE FUMARATE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- SEROQUEL XR · QUETIAPINE FUMARATE 50MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Quetiapine" as an intervention, any sponsor and status, largest first.
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT05480150 · 10,000 participants (planned) · Start Nov 1, 2021 · Primary completion Dec 31, 2026
Drug: Escitalopram Oxalate Tablets; Quetiapine Fumarate Tablets and 1 more · For: Major Depressive Disorder; Bipolar Disorder, Mixed; Affective; Disorder, Organic
Sites: Hangzhou, China
- Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive DisorderPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00278941 · 3,000 participants · Start Dec 2005
Drug: Quetiapine Fumarate Sustained Release · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Mesa, Arizona · 168 sites in all
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01727726 · 2,182 participants · Start Dec 2012 · Primary completion Oct 17, 2016
Drug: Brexpiprazole; Seroquel XR and 1 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 76 sites in all
- Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major DepressionPivotal-lookingCompleted
University of SaskatchewanAcademic, hospital or other
NCT03207438 · 1,790 participants · Start Apr 2006 · Primary completion Jul 2007
Drug: Quetiapine 50 MG Extended Release Oral Tablet; Quetiapine Fumarate XR 150-300 mg and 1 more · For: Depressive Disorder, Major
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
- Quetiapine Fumarate Bipolar Maintenance MonotherapyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00314184 · 1,255 participants · Start Mar 2005
Drug: quetiapine fumarate · For: Bipolar Disorder
Sites: Cerritos, California; San Diego, California; Santa Ana, California · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective9,887
- off label use9,865
- insomnia8,363
- toxicity to various agents8,318
- diabetes mellitus8,095
- somnolence7,358
- fatigue7,022
- drug interaction6,787
- weight increased6,710
- anxiety6,689
- nausea6,604
- depression6,467
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,549 |
| 2005 | 1,921 |
| 2006 | 3,134 |
| 2007 | 5,530 |
| 2008 | 3,326 |
| 2009 | 7,688 |
| 2010 | 9,164 |
| 2011 | 10,170 |
| 2012 | 10,999 |
| 2013 | 4,481 |
| 2014 | 5,545 |
| 2015 | 7,047 |
| 2016 | 6,970 |
| 2017 | 8,436 |
| 2018 | 9,760 |
| 2019 | 10,016 |
| 2020 | 10,161 |
| 2021 | 9,134 |
| 2022 | 8,643 |
| 2023 | 8,868 |
| 2024 | 8,920 |
| 2025 | 8,430 |
| 2026 | 6,387 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Seroquel XR (Quetiapine Fumarate)
2024 spending
$7.5M
Beneficiaries
951
7,036 claims
Per beneficiary
$7,869
$18.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,776,733 |
| 2021 | $12,146,599 |
| 2022 | $10,819,557 |
| 2023 | $9,338,118 |
| 2024 | $7,483,539 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials.
Lin CY, Chiang CH, Tseng MM, et al. · Eur Neuropsychopharmacol 2023 · Meta-Analysis, Systematic Review
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.
McIntyre RS, Stahl SM, Shim SR, et al. · JAMA Psychiatry 2026 · Systematic Review, Network Meta-Analysis
Sponsor: Cheplapharm Arzneimittel Gmbh
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.